PMC

Obtained from rigid and flexible docking by AutoDock 4.2 are shown in the form of LigPlot: (A) Schematic representation of BSA molecule (Trp-213 is in red, naringin is in yellow and naringin palmitate is in green), (B) flexible docking of naringin and naringin palmitate. (C) rigid docking of naringin and naringin palmitate.

(A) Displacement of warfarin from BSA-warfarin complex by naringin (B) Displacement of warfarin from BSA-warfarin complex by naringin palmitate (C) Displacement of ibuprofen from BSA-ibuprofen complex by naringin (D) Displacement of ibuprofen from BSA-ibuprofen complex by naringin palmitate (c _BSA = c _warfarin = 1.5×10⁻⁶ M, c _ibuprofen = 1.0×10⁻⁶ M, a→j: c _naringin, c _{naringin palmitate} = 0, 1.5, 2.5, 5.0, 10, 15, 20, 30, 40, 50×10⁻⁶ M)).

(A) naringin and (B) naringin palmitate (c _BSA = c _naringin = c _{naringin palmitate} = 1.5×10⁻⁶ M).

Flow cytometry analyzed the profiles of immunocytes in the intraepithelial and intraepithelial propria of colon tissues. (A) Naringin prevented the infiltration of M-MDSCs as determined by anti-CD11b⁺Ly6C⁺. A-a. normal mice. A-b. model mice. A-c. Naringin 50 mg/kg; A-d. Naringin 100 mg/kg; A-e. Aspirin 100 mg/kg. (B) Naringin prevented the infiltration of G-MDSCs as determined by anti-CD11b⁺Ly6G⁺. B-a. normal mice. B-b. model mice. B-c. Naringin 50 mg/kg; B-d. Naringin 100 mg/kg; B-e. Aspirin 100 mg/kg. (C) Naringin increased CD4+ T lymphocytes as determined by anti-CD3⁺/CD4⁺. C-a. normal mice. C-b. model mice. C-c. Naringin 50 mg/kg; C-d. Naringin 100 mg/kg; C-e. Aspirin 100 mg/kg. (D) Naringin increased CD8+ T lymphocytes as determined by anti-CD3⁺/CD8⁺. (E) Naringin increased macrophages as determined by anti-CD11b⁺F4/80⁺. E-a. normal mice. E-b. model mice. E-c. Naringin 50 mg/kg; E-d. Naringin 100 mg/kg; E-e. Aspirin 100 mg/kg.